February 04, 2026 | 17:39
For the first time, generic antibiotics meeting EU-GMP standards are being produced in Vietnam.
January 17, 2026 | 15:54
A subsidiary of China’s Livzon Pharmaceutical Group has registered a tender offer to acquire nearly 78 per cent of Imexpharm Corporation.
November 20, 2025 | 17:16
Imexpharm has been named the #1 Best Place to Work in Vietnam 2025 in the pharmaceutical, medical devices, and healthcare sector category.
October 22, 2025 | 08:58
In September 2025, Imexpharm’s profit before tax surged by 101 per cent, while EBITDA increased by 48 per cent.
July 21, 2025 | 11:55
Vietnam’s pharmaceutical sector is advancing through innovation, regulation, and sustainability to help build a stronger national healthcare system.
July 21, 2025 | 11:22
Imexpharm has reported strong first half results for 2025, with net revenue up 22 per cent on-year.
May 27, 2025 | 11:19
China's Livzon Pharmaceutical Group Inc. will spend VND5.73 trillion ($221 million) to acquire almost 65 per cent of Imexpharm Corporation.
May 19, 2025 | 09:00
Imexpharm is pioneering the development of high-tech, high-value pharmaceuticals.
April 29, 2025 | 11:43
Imexpharm has approved its 2025 growth plan, targeting total revenue of VND2.98 trillion
March 19, 2025 | 09:00
Green growth is becoming essential for pharmaceutical companies in the face of increasingly severe climate change.
February 25, 2025 | 09:00
Vietnamese pharmaceutical companies are gunning for growth.
October 19, 2024 | 10:53
On October 18, Imexpharm Corporation announced its third quarter results.
September 23, 2024 | 09:00
Imexpharm is driving significant growth by boosting research and development into high-tech pharmaceuticals.
August 28, 2024 | 09:00
Imexpharm Pharmaceutical JSC (IMP) is investing heavily in high-quality pharmaceutical production technology to meet international standards.
August 02, 2024 | 20:00
Imexpharm Pharmaceutical JSC was honoured at the Top 50 Corporate Sustainability Awards (CSA 2023) organised by Nhip Cau Dau Tu magazine on August 2.